PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
56.13
ESG score 90-95% of Biotechnology median of 60.59. John Neff would demand higher returns to compensate for below-average ESG risk management.
51.62
Environmental score 90-95% of Biotechnology median of 55.60. John Neff would demand higher returns to compensate for below-average climate risk management.
57.46
Social score 90-95% of Biotechnology median of 63.66. John Neff would demand higher returns to compensate for below-average stakeholder management.
59.31
Governance score near Biotechnology median of 62.29. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.